Advertisement

Optimal cut-off value of perfusion parameters for diagnosing prostate cancer and for assessing aggressiveness associated with Gleason score

  • Author Footnotes
    1 Tel.: +82-2-1661-7575.
    Eunkyung Cho
    Footnotes
    1 Tel.: +82-2-1661-7575.
    Affiliations
    Department of Radiology, The Catholic University of Korea, Yeouido St. Mary’s Hospital, 62, Yeouido-dong, Yeoungdeungpo-gu, Seoul, Korea, 150–713
    Search for articles by this author
  • Author Footnotes
    1 Tel.: +82-2-1661-7575.
    Dong Jin Chung
    Correspondence
    Corresponding author. Department of Radiology, Yeouido St. Mary’s Hospital, The Catholic University of Korea, 62, Yeouido-dong, Yeoundungpo-gu, Seoul, Korea. Tel.: +82-2-3779-1327; fax: +82-2-783-5288.
    Footnotes
    1 Tel.: +82-2-1661-7575.
    Affiliations
    Department of Radiology, The Catholic University of Korea, Yeouido St. Mary’s Hospital, 62, Yeouido-dong, Yeoungdeungpo-gu, Seoul, Korea, 150–713
    Search for articles by this author
  • Author Footnotes
    1 Tel.: +82-2-1661-7575.
    Dong Myung Yeo
    Footnotes
    1 Tel.: +82-2-1661-7575.
    Affiliations
    Department of Radiology, The Catholic University of Korea, Yeouido St. Mary’s Hospital, 62, Yeouido-dong, Yeoungdeungpo-gu, Seoul, Korea, 150–713
    Search for articles by this author
  • Author Footnotes
    1 Tel.: +82-2-1661-7575.
    Dongwan Sohn
    Footnotes
    1 Tel.: +82-2-1661-7575.
    Affiliations
    Department of Urology, The Catholic University of Korea, Yeouido St. Mary’s Hospital, 62, Yeouido-dong, Yeoungdeungpo-gu, Seoul, Korea, 150–713
    Search for articles by this author
  • Author Footnotes
    2 Tel.: +82-2-3450-7261.
    Yohan Son
    Footnotes
    2 Tel.: +82-2-3450-7261.
    Affiliations
    Imaging and Therapy Systems Division, SIEMENS Healthcare Korea, Poongsan Building 6th Floor, 23, Chungjeong-ro, Seodaemun-gu, Seoul, Korea, 120–714
    Search for articles by this author
  • Author Footnotes
    1 Tel.: +82-2-1661-7575.
    Taejung Kim
    Footnotes
    1 Tel.: +82-2-1661-7575.
    Affiliations
    Department of Pathology, The Catholic University of Korea, Yeouido St. Mary’s Hospital, 62, Yeouido-dong, Yeoungdeungpo-gu, Seoul, Korea, 150–713
    Search for articles by this author
  • Author Footnotes
    1 Tel.: +82-2-1661-7575.
    Sung-Tae Hahn
    Footnotes
    1 Tel.: +82-2-1661-7575.
    Affiliations
    Department of Radiology, The Catholic University of Korea, Yeouido St. Mary’s Hospital, 62, Yeouido-dong, Yeoungdeungpo-gu, Seoul, Korea, 150–713
    Search for articles by this author
  • Author Footnotes
    1 Tel.: +82-2-1661-7575.
    2 Tel.: +82-2-3450-7261.

      Abstract

      To determine cut-off value of dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) parameters for differentiation of prostate malignant from benign and cancer with high-grade Gleason score (GS) (GS>7) from low-grade GS (GS≤7), 35 patients (24 malignant and 11 benign) who underwent DCE-MRI were included. Difference between malignant and benign was statistically significant for all magnetic resonance parameters except Ve. The cut-off values were Ktrans=0.184 min−1, Kep=0.695 min−1, iAUC=4.219 mmol/l/min, and ADC=1340.5 mm2/s. A significant difference in mean values of Ktrans and Kep between cancer with high-grade GS and low-grade GS was also observed. Ktrans and Kep showed a significant correlation with GS.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Imaging
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Jemal A
        • Center MM
        • DeSantis C
        • Ward EM
        Global patterns of cancer incidence and mortality rates and trends.
        Cancer Epidemiol Biomarkers Prev. 2010; 19: 1893-1907
        • Li L
        • Wang L
        • Feng Z
        • Hu Z
        • Wang G
        • Yuan X
        • et al.
        Prostate cancer magnetic resonance imaging (MRI): multidisciplinary standpoint.
        Quant Imaging Med Surg. 2013; 3: 100-112
        • Epstein JI
        • Amin M
        • Boccon-Gibod L
        • Egevad L
        • Humphrey PA
        • Mikuz G
        • et al.
        Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens.
        Scand J Urol Nephrol Suppl. 2005; 34–63
        • Chen YJ
        • Chu WC
        • Pu YS
        • Chueh SC
        • Shun CT
        • Tseng WY
        Washout gradient in dynamic contrast-enhanced MRI is associated with tumor aggressiveness of prostate cancer.
        J Magn Reson Imaging. 2012; 36: 912-919
        • Bonekamp D
        • Jacobs MA
        • El-Khouli R
        • Stoianovici D
        • Macura KJ
        Advancements in MR imaging of the prostate: from diagnosis to interventions.
        Radiographics. 2011; 31: 677-703
        • Thompson IM
        • Pauler DK
        • Goodman PJ
        • Tangen CM
        • Lucia MS
        • Parnes HL
        • et al.
        Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter.
        N Engl J Med. 2004; 350: 2239-2246
        • Verma S
        • Turkbey B
        • Muradyan N
        • Rajesh A
        • Cornud F
        • Haider MA
        • et al.
        Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management.
        AJR Am J Roentgenol. 2012; 198: 1277-1288
        • Tofts Paul S
        • Brix Gunnar
        • Buckley David L
        Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols.
        J Magn Reson Imaging. 1999; 10: 223-232
        • Jackson A
        • Jayson GC
        • Li KL
        • Zhu XP
        • Checkley DR
        • Tessier JJL
        • et al.
        Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma.
        Br J Radiol. 2003; 76: 153-162
        • Parker GJ
        • Roberts C
        • Macdonald A
        • Buonaccorsi GA
        • Cheung S
        • Buckley DL
        • et al.
        Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI.
        Magn Reson Med. 2006; 56: 993-1000
        • Kozlowski P
        • Chang SD
        • Jones EC
        • Berean KW
        • Chen H
        • Goldenberg SL
        Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis—correlation with biopsy and histopathology.
        J Magn Reson Imaging. 2006; 24: 108-113
        • Kozlowski P
        • Chang SD
        • Meng R
        • Madler B
        • Bell R
        • Jones EC
        • et al.
        Combined prostate diffusion tensor imaging and dynamic contrast enhanced MRI at 3 T—quantitative correlation with biopsy.
        Magn Reson Imaging. 2010; 28: 621-628
        • Ocak I
        • Bernardo M
        • Metzger G
        • Barrett T
        • Pinto P
        • Albert PS
        • et al.
        Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.
        AJR Am J Roentgenol. 2007; 189: 849
        • Padhani AR
        • Gapinski CJ
        • Macvicar DA
        • Parker GJ
        • Suckling J
        • Revell PB
        • et al.
        Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA.
        Clin Radiol. 2000; 55: 99-109
        • Noworolski SM
        • Henry RG
        • Vigneron DB
        • Kurhanewicz J
        Dynamic contrast-enhanced MRI in normal and abnormal prostate tissues as defined by biopsy, MRI, and 3D MRSI.
        Magn Reson Med. 2005; 53: 249-255
        • van Dorsten FA
        • van der Graaf M
        • Engelbrecht MR
        • van Leenders GJ
        • Verhofstad A
        • Rijpkema M
        • et al.
        Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer.
        J Magn Reson Imaging. 2004; 20: 279-287
        • Langer DL
        • van der Kwast TH
        • Evans AJ
        • Trachtenberg J
        • Wilson BC
        • Haider MA
        Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI.
        J Magn Reson Imaging. 2009; 30: 327-334
        • Benjaminsen IC
        • Brurberg KG
        • Ruud EB
        • Rofstad EK
        Assessment of extravascular extracellular space fraction in human melanoma xenografts by DCE-MRI and kinetic modeling.
        Magn Reson Imaging. 2008; 26: 160-170
        • Gibbs P
        • Liney GP
        • Pickles MD
        • Zelhof B
        • Rodrigues G
        • Turnbull LW
        Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 Tesla.
        Invest Radiol. 2009; 44: 572-576
        • Oto A
        • Yang C
        • Kayhan A
        • Tretiakova M
        • Antic T
        • Schmid-Tannwald C
        • et al.
        Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis.
        AJR Am J Roentgenol. 2011; 197: 1382-1390
        • Selnaes KM
        • Heerschap A
        • Jensen LR
        • Tessem MB
        • Schweder GJ
        • Goa PE
        • et al.
        Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3 T: unbiased cancer identification by matching to histopathology.
        Invest Radiol. 2012; 47: 624-633
        • Peng Y
        • Jiang Y
        • Yang C
        • Brown JB
        • Antic T
        • Sethi I
        • et al.
        Quantitative analysis of multiparametric prostate MR images: differentiation between prostate cancer and normal tissue and correlation with Gleason score—a computer-aided diagnosis development study.
        Radiology. 2013; 267: 787-796
        • Sung YS
        • Kwon HJ
        • Park BW
        • Cho G
        • Lee CK
        • Cho KS
        • et al.
        Prostate cancer detection on dynamic contrast-enhanced MRI: computer-aided diagnosis versus single perfusion parameter maps.
        AJR Am J Roentgenol. 2011; 197: 1122-1129
        • Shukla-Dave A
        • Lee N
        • Stambuk H
        • Wang Y
        • Huang W
        • Thaler H
        • et al.
        Average arterial input function for quantitative dynamic contrast enhanced magnetic resonance imaging of neck nodal metastases.
        BMC Med Phys. 2009; 9: 4
        • Min-Ying Su
        • Chen Jeon-Hor
        Analysis of DCE-MRI for diagnosis and neoadjuvantchemotherapy monitoring of breast cancer.
        J Magn Reson Imaging. 2012; 3: 235-247
        • Evelhoch J
        • Garwood M
        • Vigneron D
        • Knopp M
        • Sullivan D
        • Menkens A
        • et al.
        Expanding the use of magnetic resonance in the assessment of tumor response to therapy: workshop report.
        Cancer Res. 2005; 65: 7041-7044
        • Luczynska E
        • Gasinska A
        • Wilk W
        Microvessel density and expression of vascular endothelial growth factor in clinically localized prostate cancer.
        Pol J Pathol. 2013; 64: 33-38
        • Tretiakova M
        • Antic T
        • Binder D
        • Kocherginsky M
        • Liao C
        • Taxy JB
        • et al.
        Microvessel density is not increased in prostate cancer: digital imaging of routine sections and tissue microarrays.
        Hum Pathol. 2013; 44: 495-502
        • Kang DE
        • Fitzsimons NJ
        • Presti JC
        • Kane CJ
        • Terris MK
        • Aronson WJ
        • et al.
        Risk stratification of men with Gleason score 7 to 10 tumors by primary and secondary Gleason score: results from the SEARCH database.
        Urology. 2007; 70: 277-282
        • Steinberg DM
        • Sauvageot J
        • Piantadosi S
        • Epstein JI
        Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings.
        Am J Surg Pathol. 1997; 21: 566-576